Company

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates
AbbVieBrise Pharmaceuticals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

Brise Pharmaceuticals Co. Ltd., a portfolio company of Sherpa Healthcare Partners, announced an update on its exclusive license agreement with AbbVie (NYSE: ABBV), originally entered into in 2024. Under the…

CSPC Pharmaceutical Initiates Phase I Clinical Trial of SYS6057 – Self‑Developed Recombinant RSV Vaccine with Dual‑Subtype Preclinical Protection

CSPC Pharmaceutical Initiates Phase I Clinical Trial of SYS6057 – Self‑Developed Recombinant RSV Vaccine with Dual‑Subtype Preclinical Protection

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China
ADC / XDCAstraZeneca

Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance
Finanical ReportsJ&J

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance

Konruns' KC1036 Proposed for CDE's SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development
CancerKonruns Pharmaceutical

Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development

Hainan Boao Research Hospital Secures Approval for China's First Medical-Food Import for Rare Metabolic Disorders
Boao Lecheng pilot zoneGastroenterology

Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders

Show More